Clinical trials: Cancer, Breast
Breast Cancer, Perioperative/Postoperative Complications
Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction
The purpose of this study is to investigate the efficacy of an alternative surgical technique and the use of fibrin sealant in preventing post-operative seroma formation.
- Trial name
- NCT01649505
- Testing
- fibrin sealant (Beriplast P, TISSEEL VH), breast reconstruction
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
- Trial name
- NCT03742986
- Testing
- Nivolumab 360mg, Paclitaxel 80mg/m^2, Doxorubicin 60mg/m^2
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
Insomnia, Fatigue
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
This is a four-arm, randomized, controlled, clinical trial examining the efficacy of of cognitive behavioral therapy (CBT)-I and armodafinil in reducing insomnia in 226 female breast cancer patients who report sleep disturbances…
- Conditions
- Insomnia, Fatigue, Breast Cancer
- Trial name
- NCT01091974
- Testing
- armodafinil, CBT-I
- Where
- 2 sites in United States
- Volunteers
- 138 people
- Sponsor
- University of Rochester
Breast Cancer, Hot Flashes
Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
RATIONALE: Estrogen can relieve the symptoms of menopause, but can also cause the growth of breast cancer cells. Flaxseed may reduce the number of hot flashes and improve mood and quality of life in postmenopausal women not…
- Conditions
- Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00956813
- Testing
- flaxseed
- Where
- 107 sites in United States
- Volunteers
- 210 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This two-part study is composed of two stages: a Phase Ib stage consisting of a dose-escalation phase and an expansion phase; and a Phase II, randomized, placebo-controlled, double-blind, multicenter stage.
- Trial name
- NCT04298918
- Testing
- Venetoclax, Trastuzumab emtansine
- Where
- 3 sites in Australia, South Korea
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation
This is a randomized controlled trial to determine the safety of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation.
- Trial name
- NCT02783690
- Testing
- Hypofractionation
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Mayo Clinic
HER-2 Positive Breast Cancer
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with human…
- Trial name
- NCT01305941
- Testing
- Everolimus, Vinorelbine, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
This single-arm, multicenter, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with whole brain radiotherapy on brain metastases in patients with HER-2 positive breast cancer.
- Trial name
- NCT01363986
- Testing
- trastuzumab [Herceptin]
- Where
- 16 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Screening Mammography
Promotora Navigator - Culturally Appropriate Patient Navigator
Although there has been interval improvement in reducing disparity in mammography utilization in medically underserved communities since the 1990s, significant disparities persist and should be addressed.
- Conditions
- Breast Cancer, Screening Mammography, Community Health Worker
- Trial name
- NCT03557801
- Testing
- Mammography with Community Health Worker (individual), Mammography with Community Health Worker (group), Standard of Care Mammography
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Breast Cancer, Breast Neoplasm
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
The purpose of this study is to evaluate the clinical benefit rate at 12 weeks from the addition of pazopanib to a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) in patients with hormone receptor positive…
- Trial name
- NCT01466972
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hope Rugo, MD
Breast Cancer
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)
This multi-center, prospective, open label study analyzed specimens from fifty subjects at two study sites. Patients scheduled to undergo breast-conserving surgery were recruited in accordance with the inclusion and exclusion…
- Trial name
- NCT01699867
- Testing
- Optical coherence tomography
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Diagnostic Photonics, Inc.
Breast Cancer
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who…
- Trial name
- NCT01225172
- Testing
- BMS-754807, letrozole
- Where
- 21 sites in United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
Overall survival (OS) is considered the most reliable cancer endpoint and used by the Health Rregulatory authorities (HRA). OS presents multiple advantages in cancer randomized controlled trials (RCT): it is universally accepted…
- Trial name
- NCT03676257
- Testing
- Chemotherapy (exclusive), Endocrine therapy (exclusive), Combination of endocrine therapy and chemotherapy
- Where
- France
- Volunteers
- 20,033 people
- Sponsor
- Institut Bergonié
Metastatic Breast Cancer
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent…
- Trial name
- TRC105 (NCT01326481)
- Testing
- TRC105, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Breast Cancer
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant…
- Trial name
- NCT01966471
- Testing
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab
- Where
- 295 sites in United States, Australia and 34 more
- Volunteers
- 1,846 people
- Sponsor
- Hoffmann-La Roche
Triple Negative Breast Cancer
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
This pilot study will provide preliminary data regarding the role of PIS in predicting the benefit of immune checkpoint inhibition with or without chemotherapy for high risk patients with TNBC and residual disease after effective…
- Trial name
- NCT03487666
- Testing
- Nivolumab, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Georgetown University
Solid Tumors and Lymphomas
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
The primary objectives of this study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or recommended dose for phase 2 study (RDP2) of alobresib as a monotherapy in participants with…
- Trial name
- NCT02392611
- Testing
- Alobresib, Exemestane, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Gilead Sciences
Triple Negative Breast Neoplasms
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs.
- Trial name
- NCT03310957
- Testing
- ladiratuzumab vedotin, Pembrolizumab
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 185 people
- Sponsor
- Seagen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.